- Home
- GKOS
GKOS
Glaukos Corporation
as of 02-18-2026 3:59pm EST
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
| Founded: | 1998 | Country: | US |
| Employees: | N/A | City: | ALISO VIEJO |
| Market Cap: | 6.3B | IPO Year: | 2015 |
| Target Price: | $133.07 | AVG Volume (30 days): | 770.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 14 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.95 | EPS Growth: | 0.36 |
| 52 Week Low/High: | $73.16 - $142.50 | Next Earning Date: | 05-14-2026 |
| Revenue: | $383,481,000 | Revenue Growth: | 21.85% |
| Revenue Growth (this year): | 23.29% | Revenue Growth (next year): | 27.74% |
| P/E Ratio: | -126.26 | Index: | N/A |
| Free Cash Flow: | -67618000.0 | FCF Growth: | N/A |
Stock Insider Trading Activity of Glaukos Corporation (GKOS)
Director
Avg Cost/Share
$127.97
Shares
15,000
Total Value
$1,915,576.23
Owned After
43,074
PRESIDENT & COO
Avg Cost/Share
$127.62
Shares
10,498
Total Value
$1,340,379.78
Owned After
100,458
CHAIRMAN & CEO
Avg Cost/Share
$115.00
Shares
186,945
Total Value
$21,498,675.00
Owned After
153,775
SEC Form 4
CHAIRMAN & CEO
Avg Cost/Share
$115.00
Shares
88,055
Total Value
$10,126,325.00
Owned After
153,775
SEC Form 4
Director
Avg Cost/Share
$107.27
Shares
5,000
Total Value
$536,350.00
Owned After
34,905
SEC Form 4
SVP & CHIEF FINANCIAL OFFICER
Avg Cost/Share
$105.00
Shares
315
Total Value
$33,075.00
Owned After
50,488
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Stapley Marc | GKOS | Director | Jan 22, 2026 | Sell | $127.97 | 15,000 | $1,915,576.23 | 43,074 | |
| Gilliam Joseph E | GKOS | PRESIDENT & COO | Jan 22, 2026 | Sell | $127.62 | 10,498 | $1,340,379.78 | 100,458 | |
| Burns Thomas William | GKOS | CHAIRMAN & CEO | Jan 16, 2026 | Sell | $115.00 | 186,945 | $21,498,675.00 | 153,775 | |
| Burns Thomas William | GKOS | CHAIRMAN & CEO | Jan 8, 2026 | Sell | $115.00 | 88,055 | $10,126,325.00 | 153,775 | |
| Kliman Gilbert H | GKOS | Director | Dec 9, 2025 | Sell | $107.27 | 5,000 | $536,350.00 | 34,905 | |
| Thurman Alex R. | GKOS | SVP & CHIEF FINANCIAL OFFICER | Nov 25, 2025 | Sell | $105.00 | 315 | $33,075.00 | 50,488 |
Compare GKOS vs Leading Stocks
See how GKOS stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "GKOS Glaukos Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.